AlphAIAlphAI — Financial news for AI agents
timothysykes.comSEP 192 min read$TWST

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

Original reporting
timothysykes.com
Published Sep 19, 2026, 3:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 6:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal — source image
Source · timothysykes.com
Decision brief

The 30-second read

$TWSTBullishHigh
01

Why it matters

The deal provides a strategic growth narrative and immediate price support, but financial fundamentals remain weak.

02

Market read

The announcement sparked a 7% intraday rally, prompting analyst upgrades and new price targets, making the stock a short‑term trading opportunity.

03

What to watch

High cash burn and negative profitability could limit upside if the AI collaboration stalls.

Relevance 7/10Novelty 7/10Timing: today

Background

Twist Bioscience is a synthetic DNA manufacturer with strong margins but ongoing losses; the Lilly deal is its first major AI partnership.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience shares jumped 7.1% after announcing a collaboration with Eli Lilly’s AI drug‑discovery platform.

Expected impact

Potential to test support around $155 and target $170‑$185 in the near term.

Evidence & confidence

The catalyst is fresh, the stock moved >5% on the news, and analysts have raised price targets, indicating strong market reaction.

Market effects

Sector

Highlights growing AI‑driven collaborations in biotech, may boost sentiment for synthetic biology peers.

Regional

U.S. biotech sector could see modest inflows as investors chase AI‑linked deals.

Global

Adds to broader narrative of pharma companies leveraging AI, relevant for global biotech investors.

Counterpoint

What could challenge this read

The partnership may not translate into near‑term revenue, and the stock remains overvalued on sales multiples.

Key entities

  • company
    Twist Bioscience Corporation

    Synthetic DNA and antibody discovery firm.

  • company
    Eli Lilly and Company

    Pharmaceutical giant providing the AI platform.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 19
$TWSTMed

TWST Surges As Twist Bioscience Wins Eli Lilly AI Deal

Twist Bioscience (TWST) stock rose 7.1% after securing an AI deal with Eli Lilly. The company reported $377M revenue, 52% gross margin, and -31.8% EBIT margin. Analysts highlight its AI-driven drug discovery capabilities but note persistent losses and rich valuation at 24x sales. Technical analysis suggests strong bullish momentum with support at $155.

timothysykes.com2 min
SEP 17
$TWSTMed

TWST Stock Hits Multi-Year High, But ‘Pharma Bro’ Martin Shkreli Calls Twist A Short

Twist Bioscience (TWST) stock reached a multi-year high, closing near $156 after a partnership with Eli Lilly's TuneLab and a price target increase from Leerink to $160. The company raised its fiscal 2026 sales guidance to $456M-$457M and aims for adjusted earnings break-even in Q4. Martin Shkreli called TWST a short, despite the surge. TWST's market cap exceeded $10B, with YTD gains of 390%.

finance.yahoo.com2 min
SEP 17
$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

timothysykes.com2 min
SEP 17
$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

timothysykes.com3 min
SEP 17
$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

stockstotrade.com3 min